Tofacitinib: A novel oral Janus kinase inhibitor for rheumatoid arthritis

News
Article

Tofacitinib is a novel JAK inhibitor, selective for JAK 1 and JAK 3.

Recent Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.